Mosapramine

From WikiMD's WELLNESSPEDIA

Mosapramine is an atypical antipsychotic used in Japan for the treatment of schizophrenia. It was approved for use in 1991. Mosapramine acts as a D2 receptor antagonist and also has high affinity for the sigma receptors, possibly playing a role in its antipsychotic effects.

Pharmacology[edit]

Mosapramine is classified as an atypical antipsychotic due to its distinct pharmacology; it has a high affinity for the D2, D3, and D4 dopamine receptors, and also for the sigma receptors. The drug has a lower affinity for the serotonin 5-HT2A and 5-HT2C receptors.

Clinical Use[edit]

In Japan, mosapramine is used for the treatment of schizophrenia. It has been found to be effective in treating both positive and negative symptoms of the disorder. The drug is usually well-tolerated, with side effects similar to those of other atypical antipsychotics.

Side Effects[edit]

Common side effects of mosapramine include drowsiness, dizziness, and dry mouth. Less common side effects can include tachycardia, hypotension, and extrapyramidal symptoms such as tremor and akathisia. Rare but serious side effects can include neuroleptic malignant syndrome and tardive dyskinesia.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Mosapramine[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Mosapramine&oldid=6336325"